Wed, August 10, 2011
Tue, August 9, 2011
Mon, August 8, 2011
Sun, August 7, 2011
Sat, August 6, 2011
Fri, August 5, 2011
Thu, August 4, 2011
Wed, August 3, 2011
Tue, August 2, 2011
Mon, August 1, 2011
Sun, July 31, 2011
Fri, July 29, 2011
Thu, July 28, 2011
Wed, July 27, 2011
[ Wed, Jul 27th 2011 ]: Market Wire
00 AM EDT
Tue, July 26, 2011
Mon, July 25, 2011
Sat, July 23, 2011
Fri, July 22, 2011
Thu, July 21, 2011
Wed, July 20, 2011
[ Wed, Jul 20th 2011 ]: Market Wire
Pfizer To Acquire Icagen
[ Wed, Jul 20th 2011 ]: Market Wire
00 a.m. EDT
Tue, July 19, 2011
Mon, July 18, 2011
[ Mon, Jul 18th 2011 ]: Market Wire
Aetna to Acquire PayFlex
Fri, July 15, 2011
Thu, July 14, 2011
Wed, July 13, 2011
Tue, July 12, 2011

Biogen Idec e Swedish Orphan Biovitrum presentano dati sulla terapia di lunga durata con fattore VIII ricombinante alla riunion

  Copy link into your clipboard //health-fitness.news-articles.net/content/2011/ .. -con-fattore-viii-ricombinante-alla-riunion.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

KYOTO, Giappone--([ BUSINESS WIRE ])--[ Biogen Idec ](NASDAQ: BIIB) e[ Swedish Orphan Biovitrum ](STO: SOBI) hanno annunciato in data odierna i dati di uno studio di fase 1/2a indicanti che la proteina di fusione Fc costituita da fattore VIII totalmente ricombinante di lunga durata dell'azienda (rFVIIIFc) era ben tollerata e ha dimostrato un aumento di circa 1,7 volte dell'emivita rispetto ad Advate® (fattore ricombinante anti-emofilico, metodo senza plasma/albumina, rFVIII), prodotto disponibile commercialmente a base di fattore VIII, in 16 pazienti trattati previamente affetti da emofilia A grave.

Galleria Fotografica/Multimediale Disponibile: [ http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6805603&lang=it ]